Advertisement
Advertisement
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
3.91
USDSponsored
-0.05
-1.26%
May 08, 15:58 UTC -4
Closed
After-Market
3.74
-0.17
-4.35%
OKUR Earnings Reports
Positive Surprise Ratio
OKUR beat 12 of 20 last estimates.
60%
Next Report
In 2 Days
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
$170.00K
/-$0.75
Implied change from Q4 25 (Revenue/ EPS)
--
/-24.24%
Implied change from Q1 25 (Revenue/ EPS)
--
/-36.97%
OnKure Therapeutics, Inc. Class A Common Stock earnings per share and revenue
On Mar 12, 2026, OKUR reported earnings of -0.99 USD per share (EPS) for Q4 25, beating the estimate of -1.17 USD, resulting in a 15.74% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.39% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.75 USD, with revenue projected to reach 170.00 thousand USD, implying an decrease of -24.24% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
FAQ
What were OnKure Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, OnKure Therapeutics, Inc. Class A Common Stock reported EPS of -$0.99, beating estimates by 15.74%, and revenue of $0.00, 0% as expectations.
How did the market react to OnKure Therapeutics, Inc. Class A Common Stock's Q4 2025 earnings?
The stock price moved up 7.39%, changed from $3.52 before the earnings release to $3.78 the day after.
When is OnKure Therapeutics, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for OnKure Therapeutics, Inc. Class A Common Stock's next earnings report?
Based on --
analysts, OnKure Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$0.75 and revenue of $170.00K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement